NCT04727229

Stellate Ganglion Block for Major Depressive Disorder.

Stellate Ganglion Block for Major Depressive Disorder: A Randomized Controlled Pilot Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Unity Health Toronto · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a feasibility study, to investigate a new treatment option for major depressive disorders by performing a Stellate Ganglion Block (SGB). A SGB is an injection of local anesthetic into the sympathetic nervous system (peripheral nervous system) located in the lower part of the neck, to relieve pain in the head, neck, upper arm, and upper chest.

Conditions

• Treatment Resistant Depression
• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Bupivacaine Hydrochloride	Injection of Bupivacaine near the stellate ganglion
DRUG	Normal Saline	Injection of Normal Saline near the stellate ganglion

Timeline

• Start date: 2021-09-23
• Primary completion: 2022-02-10
• Completion: 2022-03-10
• First posted: 2021-01-27
• Last updated: 2024-02-09

Locations

1 site across 1 country: Canada